Colibri Transcatheter Aortic Heart Valve System Study

Trial details

Who runs it

Colibri Heart Valve LLC

Trial code

NCT04029844

Record updated

21 February 2023

Original description

The Colibri Heart Valve clinical investigation ("COL-01") is a prospective, multicenter, exploratory single arm and controlled clinical investigation compared to recent historical results. This study will be conducted in about 7 European sites. The study will evaluate the safety and performance of the Colibri Transcatheter Aortic Heart Valve System for the treatment of symptomatic severe aortic stenosis via transfemoral access in high surgical risk patients.Read full original descriptionShow less

A Prospective, Single Arm Clinical Investigation Evaluating Safety and Performance of the Colibri Transcatheter Aortic Heart Valve System for the Treatment of Symptomatic Severe Aortic Stenosis Via Transfemoral Access in High Surgical Risk Patients

The Colibri Heart Valve clinical investigation ("COL-01") is a prospective, multicenter, exploratory single arm and controlled clinical investigation compared to recent historical results. This study will be conducted in about 7 European sites. The study will evaluate the safety and performance of the Colibri Transcatheter Aortic Heart Valve System for the treatment of symptomatic severe aortic stenosis via transfemoral access in high surgical risk patients.

30 subjects suffering from symptomatic severe aortic tricuspid valve stenosis and who are at high surgical risk (logistic EuroSCORE I > 20% or other risk factors not included in this score such as frailty, porcelain aorta, sequelae of chest radiation or logistic EuroSCORE I < 20% but considered at high risk by local Heart Team evaluation) will be enrolled in this clinical investigation.

The primary objective of this clinical investigation is to evaluate the all-cause mortality at 30 days post implantation. The secondary objectives are to evaluate the safety and performance of the investigational device at 30 days, 6 and 12 months, and 2, 3, 4, 5 years post implantation.

Inclusion: 1. Subject of age > 75 years; 2. Subject suffering from severe aortic tricuspid valve stenosis defined as follows: High-gradient aortic stenosis (mean pressure gradient across aortic valve > 40 mmHg or peak velocity > 4.0 m/s); 3. Subject has symptomatic aortic valve stenosis with New York Heart Association (NYHA) > Class II; 4. Subject with a documented local Heart Team (HT) agreement of high surgical risk as described in the population; 5. ECG-gated Multi-Slice Computed Tomographic (MSCT) measurements determined an aortic annulus > 22 mm and < 27.4 mm; 6. Subject deemed eligible by a TAVI Centralized Case Review Committee (CRC); 7. Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow-up requirements.

Exclusion: 5. Previous implantation of heart valve in any position; 17. Evidence of acute myocardial infarction (MI) less than 30 days before signing informed consent; 18. Any need for emergency surgery; 20. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis < 30 days prior to signing informed consent; 29. Currently participating in another drug or device trial (excluding observational registries) for which the primary endpoint has not been assessed; 31. For females, pregnancy or intention to become pregnant prior to completion of all follow-up procedures; 2. Aortic root anatomy condition or lesion preventing implantation or access to the aortic valve; 11. Multi-vessel coronary artery disease (CAD) with a Syntax Score or residual Syntax Score > 22 and/or unprotected left main coronary artery; 13. Untreated cardiac conduction disease in need of pacemaker implantation; 14. Uncontrolled atrial fibrillation (resting heart rate (HR) > 120bpm); 21. Any active bleeding that precludes anticoagulation; 22. Liver failure (Child-C); 24. Pulmonary hypertension (systolic pressure >80mmHg); 25. Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by a Forced Expiratory Volume (FEV1) < 750cc; 28. Any medical, social or psychological condition that in the opinion of the investigator precludes the subject from giving appropriate consent or adherence to the required follow-up procedures; 9. Severe left ventricular dysfunction (Left Ventricular Ejection Fraction (LVEF) < 30%); 16. Blood dyscrasias defined as: leukopenia (White Blood Cells (WBC) < 1,000/mm3), thrombocytopenia (Platelets (PLT) < 50,000/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states; 23. End-stage renal disease requiring chronic dialysis or creatinine clearance < 20cc/min; 27. A known hypersensitivity or contraindication to all anticoagulation/anti-platelet regimens (or inability to be anticoagulated for the index procedure), to cobalt chromium, to porcine and/or collagen, to glutaraldehyde or contrast media; 1. Arterial aorto-iliac-femoral axis unsuitable for transfemoral access as assessed by conventional angiography and/or multidetector computed tomographic angiography (access vessel diameter incompatible with a 16F sheath introducer); 3. Non-calcific acquired aortic stenosis; 4. Native unicuspid/bicuspid aortic valve or congenital aortic valve abnormality; 6. Severe aortic regurgitation (> 3+); 7. Severe mitral regurgitation (> 3+); 8. Severe tricuspid regurgitation (> 3+); 10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation; 12. Cardiogenic shock; 15. Active and/or suspicion of endocarditis or ongoing sepsis; 19. Recent (< 6 months of signing informed consent) CerebroVascular Accident (CVA) or Transient Ischemic Attack (TIA); 26. Refusal of blood transfusion; 30. Estimated life expectancy of less than 12 months; 32. Inability to comply with the clinical investigation requirements; 33. Subject under judicial protection, tutorship or curatorship (for France only).

ClinicalTrials.gov NCT04029844